CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Myriad jumps after agreeing to sell prenatal health testing business

By Reuters News

** Shares of genetic testing company Myriad Genetics MYGN.O rise 20.7% to $5.05 premarket

** Co says it will sell its prenatal health testing business to Labcorp LH.N for $210 million in cash, plus the value of the inventory

** MYGN says the transaction is expected to be accretive to Myriad's revenue growth and profitability, while strengthening the balance sheet

** Labcorp expects the deal to add about $160 million in revenue in year one

** Myriad's prenatal portfolio features several genetic screening products designed for pregnancy and reproductive health

** MYGN stock down 31% YTD, as of last close

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk